Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.

Myelofibrosis is a rare, chronic blood cancer (myeloproliferative neoplasm) where bone marrow is replaced by scar tissue, disrupting blood cell production.

Trial Shows Strong Spleen Reduction But Misses Symptom Endpoint

The SENTRY trial met its first co-primary endpoint, showing significant improvement in spleen volume reduction for patients treated with selinexor plus ruxolitinib.

The trial showed statistically significant improvement in spleen volume reduction of 35% or more (SVR35) for patients treated with the combination of selinexor plus ruxolitinib.

In addition, the trial demonstrated a promising overall survival signal, with a greater than 50% reduction in the risk of death compared to ruxolitinib alone.

Symptom Score Gap And Secondary Endpoints Remain Unclear

50% of patients who received the combination of selinexor plus ruxolitinib achieved a statistically significant improvement in SVR35 at week 24 compared to 28% of patients who received ruxolitinib alone.

Patients on ...